Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

292 - The Global Forecast of Prostate Cancer Drug-Treatable Populations Eligible for Targeted Anticancer Therapies (2017-2027)


05 Mar 2018


Poster display


Narendra Parihar


Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047


N. Parihar

Author affiliations

  • Epidemiology, Decision Resources Group, 560048 - Bangalore/IN


Abstract 292

Targeted anticancer therapies have been approved by the Food and Drug Administration for use in some men with metastatic castrate-resistant prostate cancer (MCRPC). This study aimed to forecast the first-line MCRPC drug-treatable populations (DTP) by global geographic/economic regions over the period 2017-2027.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings